A Phase II Study of Topotecan in Patients With Anaplastic Oligodendroglioma or Anaplastic Mixed Oligoastrocytoma
OBJECTIVES: I. Determine the efficacy of topotecan in patients with recurrent anaplastic
oligodendroglioma or anaplastic mixed oligoastrocytoma. II. Determine the qualitative and
quantitative toxicity of topotecan in this patient population on this schedule.
OUTLINE: This is a multicenter study. Patients receive intravenous topotecan over 30 minutes
daily for 5 days every 3 weeks. Treatment continues in the absence of disease progression or
unacceptable toxicity. Patients will be followed every 3 months until death.
PROJECTED ACCRUAL: Up to 30 evaluable patients will be accrued within 2-3 years.
Primary Purpose: Treatment
Karl Belanger, MD
CHUM - Hotel Dieu Hospital
United States: Federal Government